Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in Unresectable or Metastatic Chondrosarcoma
NCT01330966Phase 2Completed
- Sponsor
- Emerald Clinical
- Start
- Apr 2011
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in chondrosarcoma, sponsored by Emerald Clinical. Primary endpoint: Disease Control at Week 16. Started Apr 2011; status: completed.
02
Drugs
pazopanib
03
Conditions
chondrosarcoma
Beyond the preview
Go deeper on NCT01330966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01330966.